FDA approves REMS modification for Vivus' Qsymia

Vivus Inc. (NASDAQ:VVUS) said FDA approved a REMS modification for Qsymia phentermine/topiramate to allow certified retail pharmacies to dispense the obesity drug. The agency approved Qsymia last July with a REMS that limited the distribution of the drug to certified mail-order pharmacies. Vivus, which launched the fixed-dose combination of phentermine and topiramate in the U.S. last September, said it expects Qsymia to be available in retail pharmacies within 90 days. Vivus was up $0.62 to $11.78 on Tuesday. ...